Sandoz US News


Sandoz launches generic version of DACOGEN®

Sandoz today announced the US market introduction of decitabine for injection, a generic version of Eisai’s DACOGEN®.

FDA accepts Sandoz application for biosimilar filgrastim

Sandoz, a Novartis Group company, announced today that the US Food and Drug Administration (FDA) has accepted its Biologics License Application for filgrastim, which was filed under the new biosimilar pathway created in the Biologics Price Competition and Innovation Act of 2009 (BPCIA).

Sandoz obtains rights in US to commercialize KERYDINTM (tavaborole) topical solution, 5% from Anacor Pharmaceuticals, Inc.

Princeton, New Jersey, July 21, 2014 – Sandoz today announced an agreement with Anacor Pharmaceuticals, Inc. to obtain exclusive rights to commercialize Anacor’s drug KERYDINTM (tavaborole) topical solution, 5% in the US, through its branded dermatology business, PharmaDerm.

Sandoz Multimedia


Visit our multimedia gallery to learn about Sandoz.

Product Catalog

Use our Product Catalog tool to search our database for information regarding a specific Sandoz product in the US.

Sandoz Careers


Our people are our greatest resource. We are always looking for new colleagues to share in our passion and commitment to making the world a healthier place.

Slideshow Background Images